<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370499</url>
  </required_header>
  <id_info>
    <org_study_id>12849</org_study_id>
    <secondary_id>H9P-JE-LNDJ</secondary_id>
    <nct_id>NCT01370499</nct_id>
  </id_info>
  <brief_title>A Study of LY2216684 in Patients With Major Depression Disorder</brief_title>
  <official_title>Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Adult Patients With Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the long-term safety and tolerability of
      LY2216684 administered once daily in the adjunctive treatment with an Selective Serotonin
      Reuptake Inhibitors (SSRI) for up to approximately 1 year in patients with Major Depressive
      Disorder (MDD) who were partial responders to their SSRI treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with clinically significant events</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with suicidal behaviors and ideations measured by the Columbia-Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) total score and individual items</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in Clinical Global Impression - Severity (CGI-S)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in Fatigue Associated with Depression (FAs-D) average score and subscale scores</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in Hospital Anxiety and Depression Scale (HADS) depression and anxiety subscale scores</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in Sheehan Disability Scale (SDS) total score and subscale scores</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in EuroQol Questionnaire - 5 Dimension (EQ-5D)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 week endpoint in Arizona Sexual Experiences (ASEX) scale</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">237</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>LY2216684</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg to 18 mg Administered orally, once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2216684</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2216684</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have completed Study LNBM: NCT01173601 or Study LNBQ: NCT01187407

          -  Participants must be competent and able to give their own informed consent

        Exclusion Criteria:

          -  Participants that have had or currently have any additional ongoing Diagnostic and
             Statistical Manual of Mental Disorder, fourth edition, text revision (DSM-IV-TR) Axis
             I condition other than major depression that was considered the primary diagnosis
             within 1 year of entering trial

          -  Participants that have had any anxiety disorder that was considered a primary
             diagnosis within the past year

          -  Participants that have a current or previous diagnosis of bipolar disorder,
             schizophrenia, or other psychotic disorder

          -  Participants that have a history of substance abuse within the past 1 year, and/or
             substance dependence within the past 1 year, not including caffeine and nicotine

          -  Participants that have an Axis II disorder that, in the judgment of the investigator,
             would interfere with compliance with the study

          -  Participants that have had a lack of full response of the current depressive episode
             to 2 or more adequate courses of antidepressant therapy at a clinically appropriate
             dose for at least 4 weeks, or in the judgment of the investigator, the patient has
             treatment-resistant depression

          -  Participants that have a history of electroconvulsive therapy (ECT), transcranial
             magnetic stimulation (TMS), or psychosurgery within the last year

          -  Participants who are women who are pregnant or breastfeeding

          -  Participants who, in the opinion of the investigator, are judged to be at serious risk
             for harm to self or others

          -  Participants that have a serious or unstable medical illness

          -  Participants that have any diagnosed medical condition which could be exacerbated by
             noradrenergic agents

          -  Participants that have a history of severe allergies to more than 1 class of
             medication or multiple adverse drug reactions

          -  Participants that have a history of any seizure disorder (other than febrile seizures)

          -  Participants that have received treatment with a monoamine oxidase inhibitor (MAOI)
             within 14 days prior to entering trial or have a potential need to use an MAOI within
             3 days after discontinuation from the study

          -  Participants that require psychotropic medication other than sedative/hypnotic
             medication for sleep

          -  Participants who are taking or have received treatment with any excluded medications
             within 7 days prior to entering trial

          -  Participants that have a thyroid stimulating hormone (TSH) level outside the
             laboratory established reference range. Participants previously diagnosed with
             hyperthyroidism or hypothyroidism who have been treated with a stable dose of thyroid
             supplement for at least the past 3 months, and who are clinically and chemically
             euthyroid will be allowed to participate in the study.

          -  Participants that have initiated or discontinued hormone therapy within the previous 3
             months prior to enrollment

          -  Participants that have initiated psychotherapy, change in intensity of psychotherapy
             or other nondrug therapies (such as acupuncture or hypnosis) within 6 weeks prior to
             enrollment or at any time during the stud.

          -  Participants have a positive urine drug screen (UDS) for any substances of abuse on
             entering trial

          -  Participants have significantly violated rules that a patient must comply with during
             Study LNBM or Study LNBQ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>270-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>800-0226</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukushima</city>
        <zip>961-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>0600-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>660-0882</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>238-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagano</city>
        <zip>399-8301</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saga</city>
        <zip>843-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>170-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <disposition_first_submitted>April 14, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 14, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 6, 2014</disposition_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Phenylethyl Alcohol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 19, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

